Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.52 |
| ▸ | DRD3 | P35462 | 10/20 | 0.52 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708167 | 0.89 | DRD4 (0.55) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL7463234 | 0.86 | DRD4 (0.51) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL4589196 | 0.79 | DRD4 (0.57) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL6969008 | 0.76 | DRD4 (0.61) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL2395932 | 0.76 | DRD4 (0.67) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15024205 | 0.75 | DRD4 (0.59) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL3097419 | 0.75 | SIGMAR1 (0.44) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL10287534 | 0.74 | SIGMAR1 (0.71) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL6585625 | 0.73 | DRD4 (0.63) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL29188191 | 0.73 | DRD4 (0.67) | DRD4DRD3DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383768-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-7030128-B2 | Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction | MERCK SHARP & DOHME LTD. (GB) | 2006-04-18 | — | — | US | disclosed |
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1383768-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092533-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA4 | DRD4 251/4885DRD3 175/4885DRD2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.